In accordance with these findings, the present study showed that linagliptin suppressed TNF-α–induced inflammation in vitro and LPS-induced inflammation in vivo, suggesting its potential to be an adjuvant treatment for sepsis and other inflammation-related diseases. This evidence concerns the gene TNF and Sepsis.